Pancreatic Cancer Research

ResearcherPrincess Margaret Cancer CentreActive in the last 2 years

Arndt Vogel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0560-5538; OpenAlex author ID A5059190497, A5079645039. Sources: ClinicalTrials.gov.

Their work

Papers
9 (first author 1, last author 0)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: 2 trials · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 9

  1. ESMO podcast on upper GI cancers: highlights in hepatocellular carcinoma and pancreatic cancer from ESMO 2025. First author DOI 10.1016/j.esmogo.2025.100277↗
  2. Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO … Co-author DOI 10.1007/s00432-024-05954-5↗
  3. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Co-author DOI 10.2217/fon-2023-0963↗
  4. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Co-author DOI 10.1016/j.annonc.2023.08.009↗
  5. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life resu… Co-author DOI 10.1002/ijc.33336↗
  6. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-con… Co-author DOI 10.1016/j.ctrv.2016.09.001↗
  7. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from… Co-author DOI 10.1186/s12885-016-2798-8↗
  8. Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Co-author DOI 10.1159/000441310↗
  9. First-line nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer from routine clinical practice. Co-author PMID 25398812↗

Trials 2

  1. PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) Principal investigator NCT04484636↗
  2. The PLATON Network Principal investigator NCT05489250↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 2 shared papers, 2023–2026 · strength 0.67
  2. Jeroen Dekervel · 1 shared paper, 2026 · strength 0.50
  3. Salah‐Eddin Al‐Batran · 1 shared paper, 1 shared trial, 2015–2020 · strength 0.41
  4. Ángela Lamarca Lete · 2 shared papers, 2023–2024 · strength 0.37
  5. Salah-Eddin Al-Batran · 1 shared trial, 2020 · strength 0.36
  6. Hye Jin Choi · 1 shared paper, 2024 · strength 0.20
  7. Makoto Ueno · 1 shared paper, 2024 · strength 0.20
  8. Michael Jon Pishvaian · 1 shared paper, 2024 · strength 0.20
  9. Changhoon Yoo · 1 shared paper, 2024 · strength 0.20
  10. Chigusa Morizane · 1 shared paper, 2024 · strength 0.20
  11. Talia Golan · 1 shared paper, 2023 · strength 0.17
  12. Thierry Conroy · 1 shared paper, 2023 · strength 0.17
  13. Thilo Hackert · 1 shared paper, 2023 · strength 0.17
  14. Thomas Theodor Werner Seufferlein · 1 shared paper, 2023 · strength 0.17
  15. Michel Pierre Ducreux · 1 shared paper, 2023 · strength 0.17
  16. Gerald W. Prager · 1 shared paper, 2023 · strength 0.17
  17. Per Pfeiffer · 1 shared paper, 2023 · strength 0.17
  18. Janna-Lisa Velthaus · 1 shared paper, 2024 · strength 0.15
  19. Sabrina Sulzer · 1 shared paper, 2024 · strength 0.15
  20. Stefanie Hegenberg · 1 shared paper, 2024 · strength 0.15
  21. Céline Lugnier · 1 shared paper, 2024 · strength 0.15
  22. Annika Kurreck · 1 shared paper, 2024 · strength 0.15
  23. Heiko Becker · 1 shared paper, 2024 · strength 0.15
  24. Maximilian Reichert · 1 shared paper, 2024 · strength 0.15
  25. Timm M. Reißig · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.